A precision neuroscience company.
Our vision is to positively impact the lives of individuals affected with neurodegenerative diseases. Historically drug development in neurodegenerative diseases has been notoriously challenging and suffered dismal success rates. A major reason for this failure to advance therapies in these diseases can be attributed to the inability of novel therapeutics to affect the precise molecular cause of the pathology associated with each disease. By understanding the genetic and molecular factors that underlie neurodegenerative states, Arkuda Therapeutics aims to change that.
- Gerhard Koenig, PhD President & CEO
- Duane Burnett, PhD Sr. Vice President, Discovery
- Toni Williamson, PhD Sr. Vice President, Pharmacology & Translational Research